AB1676 REASSESSMENT OF THE SIGNIFICANCE OF PATIENT GLOBAL ASSESSMENT IN REMISSION CRITERIA FOR RHEUMATOID ARTHRITIS IN TERMS OF 68/66 JOINT COUNTS

Background One rationale for including patient global assessment (PtGA) in Boolean remission is that PtGA ≤1 reduces the probability of joint findings outside 28 joints and complements limitations 28-joint count [1]. Meanwhile, criterion has been questioned, leading to establishment Boolean2.0 or proposal 3V-remission [2-3]. However, significance as a complement forgotten. Objectives This study aimed evaluate discriminative power presence within framework real-world setting. Methods We analyzed 8,684 patients with rheumatoid arthritis who achieved (28-tender (TJC), 28-swollen (SJC) C-reactive protein (mg/dL) all ≤1) registered National Database Rheumatic Diseases Japan (NinJa) 2020, large observational database. Based on TJC68 SJC66, were divided into two groups without (JFO28). The values distributions compared between groups, positive likelihood ratio no was calculated, varying cutoff PtGA. Receiver Operating Characteristic (ROC) analysis performed assess JFO28 optimal cut-off value. Results Among patients, 6,901 1,783 JFO28. significantly higher (the difference 25% trimmed mean, 1.12 [95% CI, 1.01 1.24]). distribution largely overlapping (Figure 1). About 12%, 15%, 21% had when 1.0, 2.0 (Boolean2.0), none (3V-remission), respectively. ratios 1.90 1.44 1.0 2.0, area under ROC curve 0.68 0.66 0.69], indicating low power. value based Youden index. Figure 1. Conclusion A seems reasonable terms 68/66 findings. It may be pragmatic separately accordance concept dual target therapy because achieving 3V-remission. our results suggested there need extend criteria joints, considering not few even if they reached References [1]Felson DT, et al . Arthritis Rheum 2011;63(3):573-86. [2]Studenic P, Ann Dis 2023;82(1):74-80. [3]Ferreira RJO, 2021;80(3):293-303. Acknowledgements authors would like acknowledge investigators 2020. also Akiko Komiya, curated NinJa database, Satomi Hanawa, assisted administrative work. Disclosure Interests Takahiro Nishino: None declared, Shigeto Tohma Speakers bureau: Pfizer inc., Abbie Co., Ltd., Eisai LTD., Janssen Pharmaceutical K. K., Celltrion healthcare Consultant of: Mitsubishi-Tanabe Pharma Grant/research support from: Chugai Toshihiro Matsui AbbVie, Asahikasei Corp., Astellas, Co, Ltd. Eli Lilly Japan, Ono Inc.,